A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

• Status: COMPLETED
• Trial end date: 2024-12-30

Summary

The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.

• Phase: PHASE1

Details

• Lead Sponsor: Bellus Health Inc. - a GSK company